SCHEMBL73161

SCHEMBL73161

O=C(CCc1ccc2c(c1)sc1nc(-c3ccc(NC(=O)N4CCOCC4)cc3)cn12)N1CCOCC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 18/20 0.72
KDR P35968 2/20 0.47
BMPR1B O00238 1/20 0.47
MUSK O15146 1/20 0.47
EPHB6 O15197 1/20 0.47
MAP3K7 O43318 1/20 0.47
RIPK2 O43353 1/20 0.47
PAK3 O75914 1/20 0.47
STK10 O94804 1/20 0.47
MAP4K4 O95819 1/20 0.47
ABL1 P00519 1/20 0.47
NTRK1 P04629 1/20 0.47
LCK P06239 1/20 0.47
CSF1R P07333 1/20 0.47
YES1 P07947 1/20 0.47
LYN P07948 1/20 0.47
RET P07949 1/20 0.47
PDGFRB P09619 1/20 0.47
KIT P10721 1/20 0.47
PDGFRA P16234 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3452684 0.88 FLT3 (0.65) FLT3LMNARXFP1
SCHEMBL3452680 0.86 FLT3 (0.63) FLT3LMNARXFP1
SCHEMBL74014 0.84 FLT3 (1.00) FLT3KDRBMPR1BMUSKEPHB6
SCHEMBL73133 0.78 FLT3 (0.54) FLT3LMNARXFP1
SCHEMBL74508 0.77 FLT3 (0.88) FLT3KDRBMPR1BMUSKEPHB6
SCHEMBL73233 0.76 FLT3 (0.87) FLT3KDRBMPR1BMUSKEPHB6
SCHEMBL73580 0.76 FLT3 (1.00) FLT3KDRBMPR1BMUSKEPHB6
SCHEMBL74833 0.75 FLT3 (0.68) FLT3KDRBMPR1BMUSKEPHB6
SCHEMBL73364 0.75 FLT3 (0.56) FLT3KDRBMPR1BMUSKEPHB6
SCHEMBL74354 0.75 FLT3 (0.92) FLT3KDRBMPR1BMUSKEPHB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129374-B2 Method of using imidazolothiazole compounds for the treatment of disease AMBIT BIOSCIENCE CORPORATION (US) 2012-03-06 US claimed
US-8129374-B2 Method of using imidazolothiazole compounds for the treatment of disease AMBIT BIOSCIENCE CORPORATION (US) 2012-03-06 US disclosed